Deal overview
| Target | CATALENT INC |
|---|---|
| Bidder | NOVO HOLDINGS A/S |
| Price | £90.00 Full version or £25.00 Light version |
| Publication Date | Feb 05, 2024 |
| Abstract | On 5 February 2024, the Danish life sciences investor Novo Holdings A/S ("Novo") announced a recommended cash offer for 100% of the quoted US pharmaceuticals manufacturer Catalent Inc ("Catalent"). Novo would pay US$ 63.5 per Catalent share, which implied an equity value of US$ 11.7 billion for 100% of Catalent's share capital. Elliott Investment Management LP and certain ... |
| Number of pages (Full version) | 9 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
